vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and DOUGLAS DYNAMICS, INC (PLOW). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $184.5M, roughly 1.3× DOUGLAS DYNAMICS, INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 7.0%, a 4.2% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 28.6%). DOUGLAS DYNAMICS, INC produced more free cash flow last quarter ($92.8M vs $29.1M). Over the past eight quarters, DOUGLAS DYNAMICS, INC's revenue compounded faster (38.9% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
General Dynamics Corporation (GD) is an American industrial and technology company based in Reston, Virginia. It is primarily a developer and producer of advanced military equipment of a wide variety, such as nuclear submarines, main battle tanks, and armoured fighting vehicles. It is also the manufacturer of the civilian aviation Gulfstream business jets and a provider of information technology services. The company is the 3rd largest of the top 100 contractors of the U.S. federal government...
ANIP vs PLOW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $184.5M |
| Net Profit | $27.5M | $12.8M |
| Gross Margin | — | 26.1% |
| Operating Margin | 14.1% | 10.5% |
| Net Margin | 11.1% | 7.0% |
| Revenue YoY | 29.6% | 28.6% |
| Net Profit YoY | 367.5% | 62.3% |
| EPS (diluted) | $1.14 | $0.54 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $184.5M | ||
| Q3 25 | $227.8M | $162.1M | ||
| Q2 25 | $211.4M | $194.3M | ||
| Q1 25 | $197.1M | $115.1M | ||
| Q4 24 | $190.6M | $143.5M | ||
| Q3 24 | $148.3M | $129.4M | ||
| Q2 24 | $138.0M | $199.9M | ||
| Q1 24 | $137.4M | $95.7M |
| Q4 25 | $27.5M | $12.8M | ||
| Q3 25 | $26.6M | $8.0M | ||
| Q2 25 | $8.5M | $26.0M | ||
| Q1 25 | $15.7M | $148.0K | ||
| Q4 24 | $-10.3M | $7.9M | ||
| Q3 24 | $-24.2M | $32.3M | ||
| Q2 24 | $-2.3M | $24.3M | ||
| Q1 24 | $18.2M | $-8.4M |
| Q4 25 | — | 26.1% | ||
| Q3 25 | — | 23.5% | ||
| Q2 25 | — | 31.0% | ||
| Q1 25 | — | 24.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 30.7% | ||
| Q1 24 | — | 19.8% |
| Q4 25 | 14.1% | 10.5% | ||
| Q3 25 | 15.9% | 8.7% | ||
| Q2 25 | 6.6% | 19.0% | ||
| Q1 25 | 13.3% | 2.8% | ||
| Q4 24 | -2.3% | 9.0% | ||
| Q3 24 | -13.8% | 35.4% | ||
| Q2 24 | 3.7% | 18.2% | ||
| Q1 24 | 14.8% | -6.7% |
| Q4 25 | 11.1% | 7.0% | ||
| Q3 25 | 11.7% | 4.9% | ||
| Q2 25 | 4.0% | 13.4% | ||
| Q1 25 | 8.0% | 0.1% | ||
| Q4 24 | -5.4% | 5.5% | ||
| Q3 24 | -16.3% | 24.9% | ||
| Q2 24 | -1.7% | 12.2% | ||
| Q1 24 | 13.2% | -8.7% |
| Q4 25 | $1.14 | $0.54 | ||
| Q3 25 | $1.13 | $0.33 | ||
| Q2 25 | $0.36 | $1.09 | ||
| Q1 25 | $0.69 | $0.00 | ||
| Q4 24 | $-0.45 | $0.35 | ||
| Q3 24 | $-1.27 | $1.36 | ||
| Q2 24 | $-0.14 | $1.02 | ||
| Q1 24 | $0.82 | $-0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | — |
| Total DebtLower is stronger | — | $144.0M |
| Stockholders' EquityBook value | $540.7M | $281.4M |
| Total Assets | $1.4B | $626.7M |
| Debt / EquityLower = less leverage | — | 0.51× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | — |
| Q4 25 | — | $144.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $147.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $281.4M | ||
| Q3 25 | $505.8M | $275.3M | ||
| Q2 25 | $436.8M | $273.3M | ||
| Q1 25 | $418.6M | $258.9M | ||
| Q4 24 | $403.7M | $264.2M | ||
| Q3 24 | $405.9M | $260.8M | ||
| Q2 24 | $455.8M | $236.7M | ||
| Q1 24 | $452.0M | $217.2M |
| Q4 25 | $1.4B | $626.7M | ||
| Q3 25 | $1.4B | $694.9M | ||
| Q2 25 | $1.3B | $671.5M | ||
| Q1 25 | $1.3B | $621.0M | ||
| Q4 24 | $1.3B | $590.0M | ||
| Q3 24 | $1.3B | $665.6M | ||
| Q2 24 | $920.8M | $617.0M | ||
| Q1 24 | $914.5M | $577.1M |
| Q4 25 | — | 0.51× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.56× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $95.9M |
| Free Cash FlowOCF − Capex | $29.1M | $92.8M |
| FCF MarginFCF / Revenue | 11.8% | 50.3% |
| Capex IntensityCapex / Revenue | 0.5% | 1.7% |
| Cash ConversionOCF / Net Profit | 1.10× | 7.47× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $63.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $95.9M | ||
| Q3 25 | $44.1M | $-8.5M | ||
| Q2 25 | $75.8M | $-11.4M | ||
| Q1 25 | $35.0M | $-1.3M | ||
| Q4 24 | $15.9M | $74.4M | ||
| Q3 24 | $12.5M | $-14.2M | ||
| Q2 24 | $17.4M | $2.5M | ||
| Q1 24 | $18.3M | $-21.6M |
| Q4 25 | $29.1M | $92.8M | ||
| Q3 25 | $38.0M | $-11.4M | ||
| Q2 25 | $71.8M | $-14.3M | ||
| Q1 25 | $32.5M | $-3.5M | ||
| Q4 24 | $13.5M | $70.2M | ||
| Q3 24 | $7.7M | $-15.2M | ||
| Q2 24 | $13.0M | $836.0K | ||
| Q1 24 | $13.7M | $-22.4M |
| Q4 25 | 11.8% | 50.3% | ||
| Q3 25 | 16.7% | -7.1% | ||
| Q2 25 | 34.0% | -7.4% | ||
| Q1 25 | 16.5% | -3.0% | ||
| Q4 24 | 7.1% | 48.9% | ||
| Q3 24 | 5.2% | -11.8% | ||
| Q2 24 | 9.4% | 0.4% | ||
| Q1 24 | 10.0% | -23.4% |
| Q4 25 | 0.5% | 1.7% | ||
| Q3 25 | 2.7% | 1.8% | ||
| Q2 25 | 1.9% | 1.5% | ||
| Q1 25 | 1.3% | 1.9% | ||
| Q4 24 | 1.3% | 2.9% | ||
| Q3 24 | 3.2% | 0.8% | ||
| Q2 24 | 3.2% | 0.8% | ||
| Q1 24 | 3.3% | 0.8% |
| Q4 25 | 1.10× | 7.47× | ||
| Q3 25 | 1.66× | -1.07× | ||
| Q2 25 | 8.87× | -0.44× | ||
| Q1 25 | 2.23× | -9.03× | ||
| Q4 24 | — | 9.41× | ||
| Q3 24 | — | -0.44× | ||
| Q2 24 | — | 0.10× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PLOW
| Work Truck Solutions | $101.5M | 55% |
| Transferred At Point In Time | $83.1M | 45% |
